BiondVax Pharmaceuticals is UNDERVALUED at 7.80 per share with modest projections ahead. BiondVax Pharmaceuticals is unstable given 1 month investment horizon.
BiondVax Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had 0.12% of return per unit of risk over the last month. Our standpoint towards foreseeing the risk of a stock is to use both market data as well as company specific technical data. We were able to break down twenty-one different
technical indicators, which can help you to evaluate if expected returns of 1.04% are justified by taking the suggested risk. Use BiondVax Pharmaceuticals
mean deviation of 7.0, and Risk Adjusted Performance of
(0.05) to evaluate company specific risk that cannot be
diversified away.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include BiondVax Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Potential BiondVax Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although BiondVax Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in BiondVax Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BiondVax Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of BiondVax Pharmaceuticals
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of BiondVax Pharmaceuticals performance into the future periods or doing a reasonable stock valuation. The intrinsic value of BiondVax Pharmaceuticals shares is the value that is considered the true value of the share. If
the intrinsic value of BiondVax is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares BiondVax Pharmaceuticals. Please read more on our
fundamental analysis page.
Watch out for price decline
Please consider monitoring BiondVax Pharmaceuticals on a daily basis if you are holding a position in it. BiondVax Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as BiondVax Pharmaceuticals stock to be traded above the $1 level to remain listed. If BiondVax Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is BiondVax Pharmaceuticals's Liquidity
BiondVax Pharmaceuticals
financial leverage refers to using borrowed capital as a funding source to finance BiondVax Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. BiondVax Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to BiondVax Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of BiondVax Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between BiondVax Pharmaceuticals's total debt and its cash.
Details
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of BiondVax Pharmaceuticals is not uncomon. Institutional investors typically avoid acquiring a high percentage of BiondVax Pharmaceuticals stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of BiondVax is distributed among investors.
Ownership Allocation
The
market capitalization of BiondVax Pharmaceuticals is $43.23 Million. BiondVax Pharmaceuticals retains significant amount of outstanding shares owned by
insiders. An
insider is usually defined as a CEO, other corporate executive, director, or
institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative
profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
| Retail Investors58.84% | Insiders37.1% | |
| Retail Investors | 58.84 |
| Insiders | 37.1 |
| Institutions | 4.06 |
Asset Utilization
One of the ways to look at asset utilization of BiondVax is to check how much profit was generated for every dollar of assets it reports. BiondVax Pharmaceuticals shows a negative utilization of assets of -67.84 percent, losing $0.68 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of BiondVax Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.
| Current Assets70.8 M | Assets Non Current52.9 M |
| Current Assets | 70.84 Million | 57.25 |
| Assets Non Current | 52.89 Million | 42.75 |
Our take on today BiondVax Pharmaceuticals climb
The kurtosis is down to 22.78 as of today. BiondVax Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize BiondVax Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about BiondVax Pharmaceuticals volatility.
The Bottom Line
While few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, BiondVax Pharmaceuticals may offer a potential longer-term growth to sophisticated investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither pick up nor exit any shares of BiondVax Pharmaceuticals at this time. The BiondVax Pharmaceuticals risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to BiondVax Pharmaceuticals.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of BiondVax Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]